Onchilles Pharma, a pioneering biotech firm specializing in cancer treatments harnessing a unique innate immune approach for targeted and potent tumor eradication, revealed groundbreaking preclinical findings today. The data pertained to N17465 administered systemically, presented orally, and N17350 directed at tumors, showcased in a poster format at the American Association for Cancer Research® (AACR) Annual Meeting 2024. The event, held from April 5 to 10 at the San Diego Convention Center, serves as a platform for this significant unveiling.
N17350 and N17465, innovative oncology programs, leverage the innate immune system’s potent efficacy, presenting a promising new avenue for diverse cancer types. Onchilles Pharma has engineered N17350 for intratumoral delivery and N17465 for systemic IV delivery, backed by substantial preclinical data affirming their unique mechanism of action targeting the histone H1-death domain axis. This mechanism offers efficacy irrespective of tumor genetics or immune status, leading to selective cancer cell killing through immunogenic cell death.
Dr. Lev Becker, Scientific Founder of Onchilles Pharma, expressed excitement about N17465’s potential to revolutionize solid tumor treatment. Preclinical data showcased its potent, tumor-selective efficacy, immune system mobilization, and sustained responses in mouse models as a standalone therapy. These findings mark significant progress in advancing N17465 towards clinical use.
Furthermore, Dr. Becker highlighted the new data for N17350, reinforcing its mechanism of action, induction of immunogenic tumor cell death, and selective cancer cell killing across various ovarian cancer models. Onchilles Pharma intends to move N17350 into human clinical trials this year, confident in its potential as a potent and safe cancer treatment.
Court R. Turner J.D., Co-Founder & Executive Chair of Onchilles Pharma, emphasized the human validation provided by the latest data on primary tumor samples, setting the stage for forthcoming clinical trials. The potent activity and selectivity of N17350 distinguish it from other tumor-directed approaches, positioning it as a cornerstone of cancer treatment.
The presented data showcased N17465’s resistance to serine protease inhibitors, induction of immunogenic cell death, and efficacy across multiple cancer models. Similarly, N17350 demonstrated its ability to selectively kill cancer cells while sparing immune cells, exhibiting promising efficacy in ovarian cancer patient-derived models.
These findings underscore the potential of N17350 and N17465 as a novel class of cancer therapeutics, with expectations of strong monotherapy efficacy and potential approvals across various solid tumors by 2028. The upcoming Phase 1 trial for N17350 represents a significant milestone in oncology, offering renewed hope for effective cancer treatment.
